Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
QR-6401
- Development stage
- Preclinical
- Lead developer
- Genentech
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
QR-6401 is an orally active, highly potent, and selective macrocyclic small molecule inhibitor of cyclin-dependent kinase 2 (CDK2). Discovered by Regor Therapeutics in collaboration with Tencent AI Lab using generative artificial intelligence models and structure-based drug design, QR-6401 is designed to target CDK2-dependent cancers and overcome resistance to CDK4/6 inhibitors. In preclinical studies, QR-6401 demonstrated robust antitumor efficacy in OVCAR3 ovarian cancer xenograft models. In September 2024, Genentech (a member of the Roche Group) acquired Regor's portfolio of next-generation CDK inhibitors, which includes QR-6401, for global clinical development, manufacturing, and commercialization.
02
Targets
CDK1 (Cyclin-dependent kinase 1)CDK2 (Cyclin-dependent kinase 2)CDK4 (Cyclin-dependent kinase 4)CDK6 (Cyclin-dependent kinase 6)CDK9 (Cyclin-dependent kinase 9)CCNE1 (Cyclin E1)GSK3 (Glycogen synthase kinase 3 beta)
Beyond the preview
Go deeper on QR-6401.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on QR-6401.